Experimental drug targets gut damage in transplant patients
NCT ID NCT05415410
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 39 times
Summary
This Phase 2 trial tested apraglutide, a drug that helps repair the gut lining, in 31 people with severe gastrointestinal graft-versus-host disease (GVHD) after a stem cell transplant. Participants had GVHD that did not respond to steroids. The study aimed to see if apraglutide is safe and can improve gut symptoms. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Instituto Portugues de Oncologia do Porto Francisco Gentil
Porto, 4200-072, Portugal
-
Martin Luther Universität Halle-Wittenberg
Halle, 06120, Germany
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
South Austin Medical Center
Austin, Texas, 78704, United States
-
Stanford Cancer Center
Stanford, California, 94305, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
Universitaetsklinikum Duesseldorf
Düsseldorf, 40225, Germany
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, 79106, Germany
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20249, Germany
-
Universitätsklinikum Köln (AoeR)
Cologne, 50937, Germany
-
Universitätsmedizin der Johannes Gutenberg - Universität Mainz
Mainz, 55131, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apraglutide
What this could lead to
If it works, this could point toward a new treatment option for severe gut complications after stem cell transplant that don't respond to steroids.
What could go wrong
This was a small, early-phase trial that was terminated early, so results are limited. The drug may not improve outcomes and could cause side effects like injection reactions or gallbladder issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.